ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly U.S. realized price impact YoY by Quarter
U.S. realized price impact YoY (%) (%)
Eli Lilly U.S. realized price impact YoY: -3.0% in Q2 2026, up 5.0 pts from a year earlier.
Latest, Q2 2026
-3.0%
Period ended Jun 30, 2026
Change on a year earlier
+5.0 pts
-8.0% in Q2 2025
History
32 quarters
Since Q1 2018
Sources
32
Documents cited below
Where the Q2 2026 figure comes from
“|| Price | (3) | (36) | (13) | (5) | (31) | (13)”
Source: Form 10-Q FY2026Q2 (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Q4 Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly U.S. realized price impact YoY (%), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev-growth-us-price
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.